Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications
The occurrence of postoperative complications may have a significant negative impact on the prognosis of patients with gastrointestinal cancers. The inflammatory response releases systemic cytokines, which may induce residual cancer cell growth. Recently, neoadjuvant chemotherapy (NAC) was found to improve the prognosis of advanced gastric cancer (GC). We hypothesize that when postoperative complications occur after gastrectomy, NAC treatment of micrometastases can prevent residual cancer cell growth.
This study included 101 patients who underwent curative resection after NAC for GC from 2005 to 2015. Clinical data, including intraoperative parameters, were collected retrospectively. Overall survival (OS) and relapse-free survival (RFS) were compared between the patients with complications and those without complications.
Of the 101 patients, 35 (34.7%) had grade 2 or higher complications. Among those with complications, the 3- and 5-year OS rates were 63.5 and 58.2% and the 3- and 5-year RFS rates 41.7 and 41.7%, respectively. Among those without complications, the 3- and 5-year OS rates were 65.9 and 56.3% and the 3- and 5-year RFS rates 51.1 and 43.9%, respectively. There was no significant difference in prognosis between the patients with complications and those without complications.
Our study is the first to demonstrate the potential of NAC to abolish the poor prognosis induced by postoperative complications after curative resection for GC.
KeywordsNeoadjuvant chemotherapy Gastric cancer Postoperative complication Micrometastases Inflammatory cytokines Prophylactic effect
Study conception and design: KE, NH, KK, TS, and TY; acquisition of the data: KE, NH, and KK; analysis and interpretation of the data: KE, NH, and KK; writing of the manuscript: KE, NH, KK, TS, and TY. All authors approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval and patient consent
The data collection and analysis were approved by the institutional review board of the Cancer Institute Hospital. Informed consent was obtained from all patients before they were included in this study.
- 8.Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–807.CrossRefPubMedGoogle Scholar
- 19.Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver 3). Gastric Cancer. 2010;2011(14):113–23.Google Scholar
- 27.Salvans S, Mayol X, Alonso S, et al. Postoperative peritoneal infection enhances migration and invasion capacities of tumor cells in vitro: an insight into the association between anastomotic leak and recurrence after surgery for colorectal cancer. Ann Surg. 2014;260:939–43.CrossRefPubMedGoogle Scholar